Anticonvulsant use and outcomes after intracerebral hemorrhage.

Review of the Utility of Prophylactic Anticonvulsant Use in Critically Ill Patients With Intracerebral Hemorrhage.

CX3CR1 Signaling on Monocytes Is Dispensable after Intracerebral Hemorrhage

Intracerebral hemorrhage is a subset of stroke for which there is no specific treatment. The Ly6Chi CCR2+ monocytes have been shown to contribute to acute injury after intracerebral hemorrhage. The other murine monocyte subset expresses CX3CR1 and lower Ly6C levels, and contributes to repair in other disease models. We hypothesized that the Ly6Clo CX3CR1+ monocytes would contribute to recovery ...

P84: Effect of Insulin-Like Growth Factor 2 (IGF2) as a Microglia-Derived Anti-Iinflammatory Ccytokine on Improving Memory Impairment Following Hippocampal Intracerebral Hemorrhage in Rat

Insulin-like growth factor 2 (IGF2) as a microglia-derived anti-inflammatory cytokine has a pivotal activity in memory consolidation. However, there is limited evidence on brain cell-originated IGF2 expression, regulation and function in pathological condition and neuro-inflammation. Hence, the present study was conducted to investigate the effect of IGF2 on improving the memory impairment in a...

Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage.

BACKGROUND AND PURPOSE Studies suggest a protective role for statins after intracerebral hemorrhage, but many failed to assess statin discontinuation, did not include postdischarge outcomes, or did not account for withdrawal of care. We studied the relationship between preintracerebral hemorrhage statin use and in-hospital statin discontinuation on stroke severity and 30-day mortality. METHOD...

Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage

Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable. Our objective was to evaluate the risk of poor functional outcomes, delayed cerebral ischemia (DCI) and delayed seizures in aSAH patients treated with levetiracetam versus phenytoin. Medical records of patients with ...